000060425 001__ 60425
000060425 005__ 20190709135529.0
000060425 0247_ $$2doi$$a10.1007/s12325-016-0473-8
000060425 0248_ $$2sideral$$a97906
000060425 037__ $$aART-2017-97906
000060425 041__ $$aeng
000060425 100__ $$aRey, E.
000060425 245__ $$aOptimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
000060425 260__ $$c2017
000060425 5060_ $$aAccess copy available to the general public$$fUnrestricted
000060425 5203_ $$aIntroduction: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patients with IBS-C that are treated with linaclotide. Methods: A group of experts in functional digestive disorders was convened to review the efficacy and safety of linaclotide and to develop an updated consensus report for the treatment of patients with IBS-C. A search was performed for English, French and Spanish language articles in PubMed. On the basis of the articles identified, an initial document was drafted addressing different issues frequently raised by general practitioners and GI specialists that are related to the prescription, efficacy and safety of linaclotide. This document was then reviewed and modified by the expert panel until a final text was agreed upon and validated. Results: Based on the evidence, the panel addressed the following recommendations: (1) Linaclotide is indicated for the treatment of moderate to severe IBS-C in adults; (2) it is recommended that patients take linaclotide continuously and not sporadically; (3) patients should be warned about the risk of diarrhea and given choices concerning how to deal with this possible side effect; (4) the absence of tachyphylaxis or potential risks implies that linaclotide treatment can be maintained for long periods of time. Conclusions: This document seeks to lay down a set of recommendations and to identify key issues that may be useful for the clinical management of IBS-C patients treated with linaclotide.
000060425 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000060425 590__ $$a3.085$$b2017
000060425 591__ $$aPHARMACOLOGY & PHARMACY$$b91 / 261 = 0.349$$c2017$$dQ2$$eT2
000060425 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b58 / 133 = 0.436$$c2017$$dQ2$$eT2
000060425 592__ $$a1.075$$b2017
000060425 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000060425 593__ $$aPharmacology (medical)$$c2017$$dQ2
000060425 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000060425 700__ $$aMearin, F.
000060425 700__ $$0(orcid)0000-0001-6522-6682$$aAlcedo, J.
000060425 700__ $$aCiriza, C.
000060425 700__ $$aDelgado-Aros, S.
000060425 700__ $$aFreitas, T.
000060425 700__ $$aMascarenhas, M.
000060425 700__ $$aMínguez, M.
000060425 700__ $$aSantos, J.
000060425 700__ $$aSerra, J.
000060425 773__ $$g(2017), [12 pp.]$$pAdv. ther.$$tADVANCES IN THERAPY$$x0741-238X
000060425 8564_ $$s516491$$uhttps://zaguan.unizar.es/record/60425/files/texto_completo.pdf$$yVersión publicada
000060425 8564_ $$s82045$$uhttps://zaguan.unizar.es/record/60425/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000060425 909CO $$ooai:zaguan.unizar.es:60425$$particulos$$pdriver
000060425 951__ $$a2019-07-09-12:01:32
000060425 980__ $$aARTICLE